<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00117026</url>
  </required_header>
  <id_info>
    <org_study_id>AkerU</org_study_id>
    <nct_id>NCT00117026</nct_id>
  </id_info>
  <brief_title>Effects of Vitamin B1 in Type 1 Diabetic Patients</brief_title>
  <official_title>Can Oral Benfotiamine Supplementation Influence Progression of Microvascular Complications in Patients With Type 1 Diabetes?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Aker</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Research Council of Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether benfotiamine supplementation can reduce
      markers of microvascular complications in type 1 diabetic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite intensive strategies designed to achieve good metabolic control, diabetic patients
      are still at a markedly increased risk of eye and kidney disease, nerve damage, limb
      amputation, stroke and myocardial infarction as a result of long-term hyperglycemia. It has
      recently been shown that supplementation with lipid soluble vitamin B1 (benfotiamine) in
      diabetic rats could effectively block three major biochemical pathways of hyperglycemic
      damage. It has also been shown that supplementation prevented the development of experimental
      diabetic retinopathy and nephropathy, without changes in glycemic control. However, the
      applicability of the above findings to humans is unknown, and the diabetic late complications
      in experimental animals do not in every aspect mirror the human diabetic complications.

      This project will allow us to evaluate the potential of benfotiamine to reduce or prevent the
      further development of microvascular disease in type 1 diabetics.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lower-limb nerve conduction velocity</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum advanced glycation end products (AGEs) and markers of inflammation (CRP, IL-6, VCAM-1)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Benfotiamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benfotiamine 300mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for benfotiamine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for benfotiamine</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benfotiamine</intervention_name>
    <description>300mg/day</description>
    <arm_group_label>Benfotiamine</arm_group_label>
    <other_name>S-benzoylthiamine O-monophoshate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes (of at least 15 years duration) as assessed by medical history.

        Exclusion Criteria:

          -  Macroalbuminuria

          -  Symptomatic gastroparesis. Diabetic nephropathy with a creatinine clearance less than
             60 cc/min.

          -  Evidence of chronic infection.

          -  History of any malignancy.

          -  Any chronic medical condition that unduly increases the risk for the potential
             enrollee as judged by study investigators.

          -  Pregnancy, breastfeeding or planned pregnancy within two years.

          -  Supplementation with thiamine &gt; 2mg per day and/or alpha-lipoic acid

          -  Chronic alcoholism/alcohol abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristian F Hanssen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Aker</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aker University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0514</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2005</study_first_submitted>
  <study_first_submitted_qc>June 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2005</study_first_posted>
  <last_update_submitted>May 8, 2013</last_update_submitted>
  <last_update_submitted_qc>May 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Kristian F. Hanssen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Diabetes Complications</keyword>
  <keyword>benfotiamine</keyword>
  <keyword>type 1 diabetes</keyword>
  <keyword>elevated urinary albumin excretion</keyword>
  <keyword>nerve function</keyword>
  <keyword>advanced glycation end products</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benphothiamine</mesh_term>
    <mesh_term>Thiamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

